Krystal Biotech (KRYS) Competitors

$192.30 -2.14 (-1.10%)

Closing price 04:00 PM Eastern

Extended Trading

$192.30 -0.01 (0.00%)

As of 05:18 PM Eastern

KRYS vs. TEVA, SMMT, ITCI, GMAB, MRNA, VTRS, RDY, ASND, SRPT, and PCVX

Should you be buying Krystal Biotech stock or one of its competitors? The main competitors of Krystal Biotech include Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Moderna (MRNA), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Sarepta Therapeutics (SRPT), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry.

Krystal Biotech vs.

Teva Pharmaceutical Industries (NYSE:TEVA) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.

: Krystal Biotech has a net margin of 30.69% compared to Teva Pharmaceutical Industries' net margin of -9.91%. Teva Pharmaceutical Industries' return on equity of 42.46% beat Krystal Biotech's return on equity.
Company Net Margins Return on Equity Return on Assets
Teva Pharmaceutical Industries -9.91% 42.46% 6.65%
Krystal Biotech 30.69% 11.41% 10.40%
: Teva Pharmaceutical Industries presently has a consensus target price of $23.43, indicating a potential upside of 49.13%. Krystal Biotech has a consensus target price of $220.00, indicating a potential upside of 14.40%. Given Teva Pharmaceutical Industries' higher probable upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Krystal Biotech.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Teva Pharmaceutical Industries
0 Sell rating(s)
1 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.86
Krystal Biotech
0 Sell rating(s)

1 Hold rating(s)

6 Buy rating(s)

1 Strong Buy rating(s)
3.00
: 54.0% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are owned by insiders. Comparatively, 14.1% of Krystal Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
: Teva Pharmaceutical Industries has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.
: In the previous week, Teva Pharmaceutical Industries had 10 more articles in the media than Krystal Biotech. MarketBeat recorded 24 mentions for Teva Pharmaceutical Industries and 14 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.16 beat Teva Pharmaceutical Industries' score of 0.73 indicating that Krystal Biotech is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Teva Pharmaceutical Industries
13 Very Positive mention(s)
0 Positive mention(s)
11 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Krystal Biotech
8 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Krystal Biotech has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Teva Pharmaceutical Industries $16.54B 1.08 -$1.64B -$1.45 -10.83
Krystal Biotech $290.52M 19.07 $10.93M $2.99 64.31
: Teva Pharmaceutical Industries received 1038 more outperform votes than Krystal Biotech when rated by MarketBeat users. Likewise, 67.87% of users gave Teva Pharmaceutical Industries an outperform vote while only 67.66% of users gave Krystal Biotech an outperform vote.
Company Underperform Outperform
Teva Pharmaceutical Industries Outperform Votes
1333
67.87%
Underperform Votes
631
32.13%
Krystal Biotech Outperform Votes
295
67.66%
Underperform Votes
141
32.34%

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	-9.91%	42.46%	6.65%
Krystal Biotech	30.69%	11.41%	10.40%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Krystal Biotech	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	13 Very Positive mention(s)	0 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Krystal Biotech	8 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$16.54B	1.08	-$1.64B	-$1.45	-10.83
Krystal Biotech	$290.52M	19.07	$10.93M	$2.99	64.31

Company	Underperform	Outperform
Teva Pharmaceutical Industries	Outperform Votes 1333 67.87%	Underperform Votes 631 32.13%
Krystal Biotech	Outperform Votes 295 67.66%	Underperform Votes 141 32.34%

Summary

Krystal Biotech beats Teva Pharmaceutical Industries on 12 of the 18 factors compared between the two stocks.

Remove Ads

Get Krystal Biotech News Delivered to You Automatically

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KRYS vs. The Competition

Export to Excel

Metric	Krystal Biotech	Biological Products Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.54B	$3.03B	$5.68B	$8.32B
Dividend Yield	N/A	1.54%	4.55%	4.02%
P/E Ratio	64.31	29.95	24.55	19.25
Price / Sales	19.07	447.85	395.72	94.09
Price / Cash	39.38	168.68	38.16	34.64
Price / Book	5.85	4.22	7.06	4.46
Net Income	$10.93M	-$71.72M	$3.19B	$247.07M
7 Day Performance	2.02%	-2.22%	1.49%	3.05%
1 Month Performance	6.18%	-9.53%	5.87%	-2.85%
1 Year Performance	13.48%	-22.57%	14.94%	4.63%

Krystal Biotech Competitors List

Export to Excel

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KRYS Krystal Biotech	4.791 of 5 stars	$192.30 -1.1%	$220.00 +14.4%	+16.2%	$5.54B	$290.52M	64.31	210	Positive News
TEVA Teva Pharmaceutical Industries	2.6255 of 5 stars	$16.74 +2.5%	$23.43 +40.0%	+16.5%	$18.97B	$16.54B	-11.54	36,800
SMMT Summit Therapeutics	2.3948 of 5 stars	$20.13 -3.2%	$34.11 +69.5%	+513.9%	$14.85B	$700,000.00	-71.89	110
ITCI Intra-Cellular Therapies	3.6048 of 5 stars	$131.45 +0.1%	$106.08 -19.3%	+90.8%	$13.98B	$680.50M	-151.09	560	Positive News
GMAB Genmab A/S	4.1611 of 5 stars	$20.80 +1.4%	$41.33 +98.7%	-35.5%	$13.76B	$21.53B	11.95	2,204
MRNA Moderna	4.1053 of 5 stars	$34.71 +0.3%	$59.60 +71.7%	-67.6%	$13.39B	$3.20B	-3.74	3,900
VTRS Viatris	2.0057 of 5 stars	$9.25 +1.6%	$10.50 +13.5%	-21.5%	$11.04B	$14.74B	-12.50	37,000
RDY Dr. Reddy's Laboratories	2.9577 of 5 stars	$13.23 +4.3%	$17.00 +28.5%	-6.7%	$11.04B	$311.31B	21.06	24,800	Gap Up
ASND Ascendis Pharma A/S	3.0809 of 5 stars	$168.84 +10.4%	$202.36 +19.9%	+15.8%	$10.25B	$363.64M	-23.78	1,017	News Coverage Positive News Gap Up High Trading Volume
SRPT Sarepta Therapeutics	4.5729 of 5 stars	$101.35 +4.3%	$170.41 +68.1%	-40.2%	$9.83B	$1.90B	81.08	1,314
PCVX Vaxcyte	2.3362 of 5 stars	$75.23 +1.2%	$147.50 +96.1%	+9.8%	$9.69B	N/A	-16.35	160	Positive News

Remove Ads

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KRYS) was last updated on 3/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Krystal Biotech (KRYS) Competitors

KRYS vs. TEVA, SMMT, ITCI, GMAB, MRNA, VTRS, RDY, ASND, SRPT, and PCVX

Krystal Biotech vs.

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRYS vs. The Competition

Krystal Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Krystal Biotech (KRYS) Competitors

KRYS vs. TEVA, SMMT, ITCI, GMAB, MRNA, VTRS, RDY, ASND, SRPT, and PCVX

Krystal Biotech vs.

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRYS vs. The Competition

Krystal Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools